Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Dow
Baxter
Merck

Last Updated: September 27, 2022

Details for Patent: 9,649,352


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 9,649,352
Title:High purity oritavancin and method of producing same
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Inventor(s): Rafai Far; Adel (Mount-Royal, CA), Krishna; Gopal (Parsippany, NJ), Ding; Min (Parsippany, NJ), Chemburkar; Sanjay R. (North Chicago, IL), Knable; Carl M. (North Chicago, IL), Petzel; James P. (North Chicago, IL), Pruyne; Julie J. (North Chicago, IL), Reamer; Douglas M. (North Chicago, IL)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ) ABBVIE INC. (Chicago, IL)
Application Number:14/801,303
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,649,352

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,649,352

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015289602 See Plans and Pricing
Brazil 112017000898 See Plans and Pricing
Canada 2955256 See Plans and Pricing
China 107206050 See Plans and Pricing
Eurasian Patent Organization 201700019 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Medtronic
Merck
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.